Compare Entegris Inc (ENTG) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Entegris Inc vs Novo Nordisk A/S — how do they compare? Entegris Inc trades at $165.24 (market cap $24.78B), while Novo Nordisk A/S trades at $38.63 (market cap $165.31B). The key difference: Novo Nordisk A/S is far larger — about 6.7× Entegris Inc's market cap, and Novo Nordisk A/S pays the higher dividend (4.71%). Which is the better fit depends on your goals — on Pluang, investors hold Entegris Inc for 41 Days and Novo Nordisk A/S for 116 Days on average.
| ENTG | NVO | |
|---|---|---|
Market Cap | $24.78B | $165.31B |
Volume | 2,648,320 | 11,432,838 |
Sector | Technology | Health |
52-Week High | $184.00 | $63.98 |
52-Week Low | $68.80 | $35.29 |
Typical Hold Time | 41 Days | 116 Days |
Enterprise Value | $27.99B | $179.56B |
Dividend Yield | 0.25% | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENTG trades at $164.22, down 1.26% on the day, with a bullish technical signal from moving averages and strong institutional interest. The company has beaten earnings estimates for the last three quarters, with Q3 2026 results expected soon. Revenue remains stable around $3.2B, while profitability metrics show a net income margin of 9.18%. Analysts maintain a strong buy consensus with a $182.43 price target, indicating potential upside.
The outlook for ENTG is positive, driven by AI-related semiconductor demand and operational improvements. Key risks include high valuation multiples and exposure to semiconductor cycle volatility. Institutional accumulation and recent patent defenses support confidence, but investors should monitor execution against earnings expectations and industry capital spending trends.
Novo Nordisk (NVO) trades at $38.41, up 0.38% with strong fundamentals including 35.35% net margin and consistent earnings beats. The stock shows bearish technical signals but maintains robust profitability with $102.43B net income. Recent news highlights pipeline developments including Wegovy pill data and FDA reviews, while competition with Eli Lilly intensifies in the obesity drug market.
NVO presents a compelling value opportunity with a 9.66 P/E ratio and 59% upside to the $44.67 consensus target. However, technical weakness and competitive pressures from Lilly's new drug candidates pose near-term risks. The company's strong cash flow generation and 59.82% ROE support long-term growth prospects despite regulatory uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Entegris Inc
Entegris Inc is a supplier of advanced materials and process solutions for the semiconductor and other high-technology industries. The company's reportable segments include Specialty Chemicals & Engineered Materials (SCEM), Microcontamination Control (MC), and Advanced Materials Handling (AMH). The SCEM segment provides high-performance & high-purity process chemistries, gases, & materials, and safe & efficient delivery systems. The Microcontamination Control (MC) segment includes solutions to purify critical liquid chemistries and process gases used in semiconductor manufacturing processes and other high-technology industries. Its geographical segments are Taiwan, North America, South Korea, Japan, China, Europe, and Southeast Asia.
Read more on ENTG →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
